Literature DB >> 1959704

Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide.

M Fried1, W Schwizer, C Beglinger, U Keller, J B Jansen, C B Lamers.   

Abstract

Cholecystokinin was previously proposed to play an important role in the regulation of postprandial insulin secretion either indirectly, by inhibiting gastric meal emptying, or directly, by acting as an incretin promoting the release of insulin. The aim of this investigation was therefore to clarify the role of endogenous cholecystokinin in the regulation of insulin release and gastric emptying applying the highly potent and specific cholecystokinin receptor antagonist loxiglumide. Five healthy volunteers were examined after an overnight fast. Gastric meal emptying was measured by the double indicator technique using a multiple lumen tube in the duodenum and 99mTc-diethylenetriamine pentaacetate as a meal marker and polyethylene glycol 4000 as a duodenal perfusion marker. Postprandial insulin, C-peptide, cholecystokinin and glucose levels were measured after ingestion of two isocaloric meals of a) Ensure (containing fat, protein and glucose), and b) a pure glucose meal (1.11 mol/l). The meals were given either with an intravenous infusion of loxiglumide (22 mumol.kg-1.h-1) or placebo. The infusion of loxiglumide markedly accelerated the gastric emptying of the mixed meal (area under curve, 5576 +/- 352 min vs 3498 +/- 109 min; p less than 0.001) and the pure glucose meal (area under curve 5662 +/- 537 min vs 3551 +/- 534 min; p less than 0.05). Simultaneously, loxiglumide induced a more rapid rise in postprandial insulin levels after both meals resulting in significantly higher (p less than 0.05) insulin levels during the first postprandial hour, but similar insulin levels in the second postprandial hour. Accordingly, we found a close correlation between meal emptying and insulin release (r = 0.748, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959704     DOI: 10.1007/bf00401517

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

Authors:  P Hildebrand; C Beglinger; K Gyr; J B Jansen; L C Rovati; M Zuercher; C B Lamers; I Setnikar; G A Stalder
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

2.  Measurement of gastric functions during digestion of ordinary solid meals in man.

Authors:  J R Malagelada; G F Longstreth; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

3.  Effect of cholecystokinin receptor antagonist on pancreatic responses to exogenous gastrin and cholecystokinin and to meal stimuli.

Authors:  S J Konturek; J Tasler; M Cieszkowski; K Szewczyk; M Hladij
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

4.  Role of cholecystokinin in regulation of gastrointestinal motor functions.

Authors:  B M Meyer; B A Werth; C Beglinger; P Hildebrand; J B Jansen; D Zach; L C Rovati; G A Stalder
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

5.  Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.

Authors:  R A Liddle; B J Gertz; S Kanayama; L Beccaria; T W Gettys; I L Taylor; R J Rushakoff; V C Williams; L D Coker
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

6.  Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans.

Authors:  R J Rushakoff; I D Goldfine; J D Carter; R A Liddle
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

7.  Glycemic index of foods: a physiological basis for carbohydrate exchange.

Authors:  D J Jenkins; T M Wolever; R H Taylor; H Barker; H Fielden; J M Baldwin; A C Bowling; H C Newman; A L Jenkins; D V Goff
Journal:  Am J Clin Nutr       Date:  1981-03       Impact factor: 7.045

8.  Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist.

Authors:  I Setnikar; M Bani; R Cereda; R Chisté; F Makovec; M A Pacini; L Revel; L C Rovati; L A Rovati
Journal:  Arzneimittelforschung       Date:  1987-06

9.  Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.

Authors:  R A Liddle; R J Rushakoff; E T Morita; L Beccaria; J D Carter; I D Goldfine
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

10.  Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK.

Authors:  F Makovec; M Bani; R Cereda; R Chistè; M A Pacini; L Revel; L C Rovati
Journal:  Pharmacol Res Commun       Date:  1987-01
View more
  12 in total

1.  Cyclic motor activity of the gallbladder maintained in a pylorus-preserving gastrectomy in dogs.

Authors:  A Enjoji; K Ura; K Ozeki; M Tsukamoto; Y Ikematsu; T Kanematsu
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  The effect of short-term dietary supplementation with glucose on gastric emptying of glucose and fructose and oral glucose tolerance in normal subjects.

Authors:  M Horowitz; K M Cunningham; J M Wishart; K L Jones; N W Read
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 3.  Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes.

Authors:  Paul M Hobbs; William G Johnson; David Y Graham
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

Review 4.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

5.  Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects.

Authors:  M Horowitz; M A Edelbroek; J M Wishart; J W Straathof
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

6.  Glucose Variability Measures as Predictors of Oral Feeding Intolerance in Acute Pancreatitis: A Prospective Pilot Study.

Authors:  Chirag J Jivanji; Varsha M Asrani; Sayali A Pendharkar; Melody G Bevan; Nicola A Gillies; Danielle H E Soo; Ruma G Singh; Maxim S Petrov
Journal:  Dig Dis Sci       Date:  2017-03-14       Impact factor: 3.199

7.  Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.

Authors:  I Imoto; M Yamamoto; D M Jia; M Otsuki
Journal:  Int J Pancreatol       Date:  1997-12

Review 8.  Disordered gastric motor function in diabetes mellitus.

Authors:  M Horowitz; R Fraser
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

9.  Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.

Authors:  T Akiyama; I Tachibana; Y Hirohata; H Shirohara; M Yamamoto; M Otsuki
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

10.  Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.

Authors:  N Watanabe; M Otsuki
Journal:  Int J Pancreatol       Date:  1993-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.